Moreover, a quantity of groups had being performing the preclinical trials to identify PCa that respond to the PTEN/AKT/mTOR inhibitors, either alone or in combination with other therapies in vitro and in vivo models [25], [43], [44], [45]. Here, AKT1 is linked to posterior cortical atrophy.